PeterHaanJohnsonMD

PubMed

• 3 citations
  The use of HER2 modulation in the adjuvant setting.
  Peter H. Johnson, Francisco J. Esteva> ;Current Oncology Reports. 2007 Jan 1
• 234 citations
  Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero
  Karin M. E. Hahn, Peter H. Johnson, Nancy Gordon, Henry Mark Kuerer, Lavinia P. Middleton, Mildred Ramirez, Wei Yang, George H. Perkins, Gabriel N. Hortobagyi, Richard...> ;Cancer. 2006 Sep 15

Journal Articles

• Vorinostat and Bortezomib as Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study  
  Tien Hoang, Toby C. Campbell, Chong Zhang, KyungMann Kim, Jill M. Kolesar, Kurt R. Oettel, Jules H. Blank, Emily G. Robinson, Harish G. Ahuja, Ron J. Kirschling, Peter..., Investigational New Drugs, 6/1/2013
• The Use of HER2 Modulation in the Adjuvant Setting  
  Peter H. Johnson and Francisco J. Esteva, Current Oncology Reports, 1/1/2007
• Update on Approaches to the treatment of non-small-cell lung cancer  
  P.H. Johnson and E.S. Kim, Oncology, 1/1/2005

Abstracts/Posters

• Nuclear staining of topoisomerase II (topo II) may predict response to anthracycline but not to taxane based neoadjuvant chemotherapy regimens.
  Peter Johnson, Savitri Krishnamurthy, Aman Buzdar, Gabriel Hortobagyi, Stacy Moulder, Breast Cancer Research and Treatment, 12/1/2006
• The Treatment of Pregnant Women with Breast Cancer and the Outcomes of the Children Exposed to Chemotherapy In Utero.
  P. Johnson, K.Gwyn, N. Gordon, L. Middleton, H. Kuerer, G. Perkins, W. Yang, G. Hortobagyi, R. Theriault, Journal of Clinical Oncology; 2005 Meeting of the American Society of Clinical Oncology, 1/1/2005